The three most-compared compounds in weight-management research are really the same idea at three levels of ambition. Semaglutide engages one receptor. Tirzepatide engages two. Retatrutide engages three. Everything else — the trial numbers, the approval status, the price per milligram — follows from that difference.
This is a research comparison of the three: what each one targets, what the trials reported, and where the evidence is genuinely comparable and where it is not.
The Receptor Difference
Each additional receptor adds a distinct mechanism, and the pharmacology is worth being precise about before comparing outcomes measured in different trials.
- Semaglutide — GLP-1 only. GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling. It is the mechanism the entire class was built on, and the reason the first generation worked as well as it did.
- Tirzepatide — GLP-1 + GIP. Adding glucose-dependent insulinotropic polypeptide agonism improved the weight-loss effect and, in the SURPASS/SURMOUNT programmes, also improved glycaemic outcomes.
- Retatrutide — GLP-1 + GIP + glucagon. The third receptor is the interesting one. Glucagon agonism is associated with increased energy expenditure and reduced liver fat, and it comes with a known risk: glucagon alone raises blood glucose. Pairing it with GLP-1 and GIP agonism is what makes the combination viable, and it is why the triple agonist produces the largest weight reductions reported in the class so far.
What the Trials Actually Reported
| Compound | Receptors | Key trial | Reported weight reduction | Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | STEP-1 (2.4 mg) | ~14.9% at 68 weeks | Approved (Ozempic / Wegovy) |
| Tirzepatide | GLP-1 + GIP | SURMOUNT-1 (15 mg) | ~20.9% at 72 weeks | Approved (Mounjaro / Zepbound) |
| Retatrutide | GLP-1 + GIP + glucagon | TRIUMPH-1 (12 mg) | 28.3% at 80 weeks; 30.3% at 104 weeks in extension data | Investigational — filing planned Q1 2027 |
| Orforglipron (context) | GLP-1, oral non-peptide | ATTAIN-1 | ~12.4% at 72 weeks at the highest dose | Approved April 2026 |
One caveat matters more than the table: these are different trials, with different populations, durations and statistical handling. Retatrutide’s 28.3% comes from an 80-week phase 3 readout; semaglutide’s figure comes from a 68-week trial run years earlier in a different patient mix. Reading across rows tells you the direction of the class, not that one molecule is exactly X% better than another.
Why Glucagon Agonism Is the Variable Everyone Is Watching
The step from one receptor to two produced a clear increment in efficacy. The step from two to three produced a larger one, and it changed the shape of the effect rather than just its size. Retatrutide’sprogramme has reported improvements in liver-fat measures alongside body-weight reduction — an effect consistent with what glucagon agonism is expected to do metabolically, and one that the dual agonists do not produce to the same degree.
That is also where the open questions sit. Glucagon agonism is why the triple agonist is pharmacologically interesting and why its tolerability profile gets scrutinised more closely than the two-receptor compounds. Class-wide gastrointestinal effects are the common thread across all three; how the extra receptor affects them is precisely what the later trial readouts are for.
Mechanism and Practical Comparison
All three are administered by injection and dosed on a weekly basis in their clinical protocols, which reflects similar effective half-lives in the range of roughly five to eight days depending on the molecule and the assay. In practical terms, the dosing interval is not what separates them — the receptor profile is.
Formulation is where the three diverge most in a research context:
- Approved products ship as prefilled pens or ready-to-use solution, in fixed strengths.
- Research material ships as a lyophilised powder in a sealed vial, in a strength you select — which is why 10 mg vials have become the standard unit for retatrutide work: they map onto the dose range the phase 3 programme studied and they keep cost per milligram predictable.
How the Three Are Compared in Practice
When comparing these compounds as research material rather than as prescription products, four things do the actual differentiating:
- Label claim versus tested content. A vial labelled 10 mg should test near 10 mg. Anything materially under that is a worse product at any price.
- Batch-level documentation. The analytical result has to correspond to the lot number on the vial, not to a generic certificate.
- Form and stability.Lyophilised powder is the stable format; how it was stored before it reached you matters as much as how you store it afterwards.
- Price per milligram. Comparing vial prices across different strengths is meaningless. Divide by total milligrams.
Which One Is “Best”?
The honest answer is that they answer different questions. Retatrutide has the strongest efficacy signal published in the class, and it also has the shortest regulatory history: it is investigational, with a filing planned for the first quarter of 2027. Tirzepatide and semaglutide are approved, widely used, and have years of real-world data behind them. Orforglipron answers a different question entirely — oral delivery, with a lower efficacy ceiling.
If your comparison is about mechanism and published effect size, the triple agonist wins. If it is about evidence maturity or availability as an approved medicine, it does not.
Where Retatrutide Research Material Comes From
Retatrutide research peptide is supplied as a lyophilised powder in a sealed vial, batch-tested, with the 10 mg strength being the unit most labs standardise on. If you are setting up a comparison against the approved compounds, the retatrutide 10 mg vial covers the dose range the phase 3 programme studied without forcing you into multiple smaller vials. Everything else in the range — peptides for fat loss, recovery and growth — sits in the same peptide catalogue.
Retatrutide vs Tirzepatide vs Semaglutide FAQ
Is retatrutide stronger than tirzepatide?
In the published trials, retatrutide produced larger average weight reductions than tirzepatide, and tirzepatide produced larger reductions than semaglutide. The comparison is directional rather than exact, because the trials differ in duration, population and analysis.
What is a triple agonist?
A molecule that activates three receptors at once. Retatrutide activates GLP-1, GIP and glucagon receptors; tirzepatide activates two; semaglutide activates one.
Is retatrutide a GLP-1?
It is a GLP-1 receptor agonist — but that describes only one of the three receptors it engages, which is why calling it “a GLP-1” undersells what distinguishes it.
Are all three available as research material?
Semaglutide and tirzepatide are both widely available as research-grade lyophilised peptides. Retatrutide is the newest of the three and the one most commonly compared against them, since it is the only one of the trio that remains unapproved.
Supplied for laboratory research purposes only. Not for human or veterinary use.